The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
When celebrities drop dress sizes fast, whispers of 'fat jabs' like Ozempic fill the air—but stars stay mum. A veteran celeb agent exposes the regulatory pitfalls, contract traps, and multimillion-dollar reasons behind the secrecy. From TV bans to brand conflicts, here's why honesty could cost them dearly.
Side-by-side photos from 2019 and 2025 make Rebel Wilson's facial transformation after shedding over 80 pounds strikingly apparent. Noticeable changes include reduced volume, minor skin elasticity loss in cheeks, neck, and around lips and eyes, plus a sharper jawline. While many attribute it to Ozempic, Wilson clarifies its limited role in her journey.
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
Sydney's superstar chef Neil Perry, behind Gran Torino, Margaret, and Qantas menus, isn't fazed by the Ozempic craze. He pledges to continue creating beautiful food for those who love to eat. In a bold GLP-1 warning, Perry hints at potential lawsuits ahead.
Trey Luker-Stewart lost 60 pounds on Ozempic, but it transformed his drinking from fun nights to anxious, emotional ones with brutal hangovers. As a Dallas bar owner, he's seen a 35% drop in alcohol sales linked to GLP-1 drugs. Doctors reveal why these medications blunt alcohol's rewards and worsen next-day effects.
Social media buzz highlights itchy skin as a surprising side effect of GLP-1 medications like semaglutide (Ozempic, Wegovy). Patients report hives and mosquito-like bites after doses. Dermatologists and weight loss experts break down causes from allergies to rapid weight loss and offer practical advice.
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
